Tumors, Aiom: "Starting Compassionate Use Program for Daraxonrasib in Pancreatic Cancer"

Il Tempo

Il Quotidiano del Sud

View article

newsbiella.it

View article

canaledieci.it

View article

Giornale Radio

View article

+4 Reposted by 4 other sources

Lean Right

Factuality

Ownership

Rome, 11 Sep. (Adnkronos Salute) - The Italian Association of Medical Oncology (Aiom) asks Revolution Medicines "to start the program of compassionate use for Daraxonrasib, thus making available free of charge the drug, before regulatory approval, in patients with metastatic pancreas cancer already treated with chemotherapy."

periodicodaily.com

Factuality

Ownership

The Italian Association of Medical Oncology (Aiom) asks Revolution Medicines "to start the program of compassionate use for Daraxonrasib, thus making available free of charge the drug, before regulatory approval, in patients with metastatic pancreatic cancer already treated with chemotherapy." It is "a targeted therapy that, although it has produced results only in [...]

Rec News | Lontani dal mainstream

notizie.it

View article

Reposted by

notizie.it

Factuality

Ownership

(Adnkronos) L'Associazione italiana di oncologia medica (Aiom) asks Revolution Medicines to start the program of compassionate use for Daraxonrasib, thus making available free of charge the drug, before regulatory approval, in patients with metastatic pancreas cancer already treated with chemotherapy. It is a targeted therapy that, although having produced so far results only in [...] L'articolo Tumori, Aiom: "Starting compassionate use program …

quotidianosanita.it

Factuality

Ownership

AIOM asks Revolution Medicines to activate also in Europe a program of compassionate use for Daraxonrasib, targeted therapy approved by the FDA in the United States in August for patients with metastatic pancreatic cancer already treated with chemotherapy. The post pancreatic cancer. Aiom: Daraxonrasib not yet available in Italy. Start immediately compassionate use is appeared first on Quotidiano Sanità.